Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Issue 5 (14th November 2019)

• Record Type: Journal Article
• Authors: Chachi, Latifa; Diver, Sarah; Kaul, Himanshu; Rebelatto, Marlon C.; Boutrin, Anmarie; Nisa, Patricia; Newbold, Paul; Brightling, Christopher
• Is Part Of: European respiratory journal. Volume 54:Issue 5(2019)
• Publication Date: 2019-11-14
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00930-2019
• Languages: English
• ISSNs: 0903-1936

Abstract

Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by interleukin (IL)-4, IL-5 and IL-13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL-5 receptor agent, benralizumab, causes depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials. Benralizumab leads to a reduction in ASM mass in asthmatic airways, which can be predicted using a computational model http://bit.ly/2OwNMBy